

Junji Uchino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7492806/publications.pdf>

Version: 2024-02-01

91
papers

1,730
citations

393982

19
h-index

344852

36
g-index

92
all docs

92
docs citations

92
times ranked

2587
citing authors

#	ARTICLE	IF	CITATIONS
1	AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells. <i>Nature Communications</i> , 2019, 10, 259.	5.8	223
2	Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). <i>Cancer</i> , 2018, 124, 606-616.	2.0	147
3	Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 1362.	1.0	102
4	Tumor Neovascularization and Developments in Therapeutics. <i>Cancers</i> , 2019, 11, 316.	1.7	85
5	Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR-mutated non-small cell lung cancer. <i>Cancer Medicine</i> , 2019, 8, 1521-1529.	1.3	82
6	ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2244-2256.	3.2	75
7	Association of Sarcopenia with and Efficacy of Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2019, 8, 450.	1.0	72
8	The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 847-853.	1.3	52
9	Retrospective Efficacy Analysis of Immune Checkpoint Inhibitor Rechallenge in Patients with Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 102.	1.0	42
10	A phase II study of afatinib treatment for elderly patients with previously untreated advanced non-small-cell lung cancer harboring EGFR mutations. <i>Lung Cancer</i> , 2018, 126, 41-47.	0.9	39
11	Clinical features of immune-related thyroid dysfunction and its association with outcomes in patients with advanced malignancies treated by PD-1 blockade. <i>Oncology Letters</i> , 2019, 18, 2140-2147.	0.8	35
12	Safety and Usefulness of Cryobiopsy and Stamp Cytology for the Diagnosis of Peripheral Pulmonary Lesions. <i>Cancers</i> , 2019, 11, 410.	1.7	34
13	Efficacy and safety of immune checkpoint inhibitor monotherapy in pretreated elderly patients with non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 761-771.	1.1	32
14	Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2021, 161, 26-33.	0.9	31
15	Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis. <i>Translational Lung Cancer Research</i> , 2022, 11, 277-294.	1.3	29
16	The clinical efficacy and safety of a fluoroquinolone-containing regimen for pulmonary MAC disease. <i>Journal of Infection and Chemotherapy</i> , 2012, 18, 146-151.	0.8	25
17	Infectivity enhanced, hTERT promoter-based conditionally replicative adenoviruses are useful for SCLC treatment. <i>Cancer Gene Therapy</i> , 2005, 12, 737-748.	2.2	24
18	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	24

#	ARTICLE	IF	CITATIONS
19	Significance of inflammatory indexes in atezolizumab monotherapy outcomes in previously treated non-small-cell lung cancer patients. <i>Scientific Reports</i> , 2020, 10, 17495.	1.6	24
20	Combination with low-dose gemcitabine and hTERT-promoter-dependent conditionally replicative adenovirus enhances cytotoxicity through their crosstalk mechanisms in pancreatic cancer. <i>Cancer Letters</i> , 2010, 294, 178-186.	3.2	23
21	Impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: a retrospective study. <i>Oncolimmunology</i> , 2021, 10, 1950411.	2.1	22
22	Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 457-466.	1.2	21
23	Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 450-460.	1.3	18
24	A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. <i>Cancer</i> , 2022, 128, 2025-2035.	2.0	18
25	The clinical efficacy and safety of micafungin-itraconazole combination therapy in patients with pulmonary aspergilloma. <i>Journal of Infection and Chemotherapy</i> , 2012, 18, 668-674.	0.8	17
26	Carcinoembryonic antigen and CYFRA 21-1 responses as prognostic factors in advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 227-234.	1.3	17
27	Osimertinib in Elderly Patients with Epidermal Growth Factor Receptor T790M-Positive Non-Small-Cell Lung Cancer Who Progressed During Prior Treatment: A Phase II Trial. <i>Oncologist</i> , 2019, 24, 593-e170.	1.9	17
28	Immune-Related Adverse Events Are Associated With Clinical Benefit in Patients With Non-Small-Cell Lung Cancer Treated With Immunotherapy Plus Chemotherapy: A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 630136.	1.3	17
29	Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer. <i>Diagnostics</i> , 2022, 12, 423.	1.3	17
30	Critical role of tumor necrosis factor receptor 1 in the pathogenesis of pulmonary emphysema in mice. <i>International Journal of COPD</i> , 2016, Volume 11, 1705-1712.	0.9	16
31	Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation. <i>Internal Medicine</i> , 2016, 55, 1621-1624.	0.3	13
32	Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer. <i>Thoracic Cancer</i> , 2019, 10, 526-532.	0.8	13
33	Impact of preexisting antinuclear antibodies on combined immunotherapy and chemotherapy in advanced non-small cell lung cancer patients. <i>Medical Oncology</i> , 2020, 37, 111.	1.2	13
34	Endocrinopathies Associated with Immune Checkpoint Inhibitor Cancer Treatment: A Review. <i>Journal of Clinical Medicine</i> , 2020, 9, 2033.	1.0	13
35	Anlotinib combined with gefitinib can significantly improve the proliferation of epidermal growth factor receptor-mutant advanced non-small cell lung cancer in vitro and in vivo. <i>Translational Lung Cancer Research</i> , 2021, 10, 1873-1888.	1.3	13
36	Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer. <i>Cancer Letters</i> , 2021, 522, 119-128.	3.2	13

#	ARTICLE	IF	CITATIONS
37	HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features. <i>Npj Precision Oncology</i> , 2022, 6, 5.	2.3	13
38	Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study. <i>Translational Lung Cancer Research</i> , 2021, 10, 3582-3593.	1.3	12
39	Expert consensus on perioperative immunotherapy for local advanced non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 3713-3736.	1.3	12
40	Species D Human Adenovirus Type 9 Exhibits Better Virus-Spread Ability for Antitumor Efficacy among Alternative Serotypes. <i>PLoS ONE</i> , 2014, 9, e87342.	1.1	12
41	Nicotine Induces Resistance to Erlotinib Therapy in Non-Small-Cell Lung Cancer Cells Treated with Serum from Human Patients. <i>Cancers</i> , 2019, 11, 282.	1.7	11
42	Chronic <i>Pseudomonas aeruginosa</i> infection-induced chronic bronchitis and emphysematous changes in CCSP-deficient mice. <i>International Journal of COPD</i> , 2016, Volume 11, 2321-2327.	0.9	10
43	Comparing three different anti-PD-L1 antibodies for immunohistochemical evaluation of small cell lung cancer. <i>Lung Cancer</i> , 2019, 137, 108-112.	0.9	10
44	Final Results from a Phase II Trial of Osimertinib for Elderly Patients with Epidermal Growth Factor Receptor t790m-Positive Non-Small Cell Lung Cancer That Progressed during Previous Treatment. <i>Journal of Clinical Medicine</i> , 2020, 9, 1762.	1.0	10
45	Safety and tolerability of PD-1/PD-L1 inhibitors in elderly and frail patients with advanced malignancies. <i>Oncology Letters</i> , 2020, 20, 14.	0.8	10
46	Association of immune checkpoint inhibitors with respiratory infections: A review. <i>Cancer Treatment Reviews</i> , 2020, 90, 102109.	3.4	9
47	Efficacy of Aprepitant in Patients with Advanced or Recurrent Lung Cancer Receiving Moderately Emetogenic Chemotherapy. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 4187-4190.	0.5	9
48	Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis. <i>Thoracic Cancer</i> , 2019, 10, 557-563.	0.8	8
49	Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation. <i>Cancers</i> , 2019, 11, 365.	1.7	8
50	Rationale and Design of a Phase II Trial of Osimertinib Combined With Bevacizumab in Patients With Untreated Epidermal Growth Factor Receptor-mutated Non-small-cell Lung Cancer and Malignant Pleural and/or Pericardial Effusion (SPIRAL II Study). <i>Clinical Lung Cancer</i> , 2019, 20, e402-e406.	1.1	8
51	Rationale and design of a phase II trial of durvalumab treatment in patients with NSCLC ineligible for stage III chemoradiotherapy following radiation monotherapy (SPIRAL-RT study). <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092784.	1.4	8
52	The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 663612.	1.3	8
53	Low-dose Epidermal Growth Factor Receptor (EGFR)-Tyrosine Kinase Inhibition of EGFR Mutation-positive Lung Cancer: Therapeutic Benefits and Associations Between Dosage, Efficacy and Body Surface Area. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 785-789.	0.5	8
54	Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab. <i>Internal Medicine</i> , 2021, 60, 3585-3588.	0.3	7

#	ARTICLE	IF	CITATIONS
55	First reported case of hemoglobin lancing in Asia detected by false low oxygen saturation on pulse oximetry. <i>International Journal of Hematology</i> , 2012, 95, 731-732.	0.7	6
56	Identifying risk factors for refractory febrile neutropenia in patients with lung cancer. <i>Journal of Infection and Chemotherapy</i> , 2012, 18, 53-58.	0.8	6
57	Vascular endothelial growth factor promoter-based conditionally replicative adenoviruses effectively suppress growth of malignant pleural mesothelioma. <i>Cancer Science</i> , 2017, 108, 116-123.	1.7	6
58	Treatment rationale and design of the SPIRAL study. <i>Medicine (United States)</i> , 2018, 97, e11081.	0.4	6
59	Successful sequential treatment of refractory tumors caused by small cell carcinoma transformation and EGFR-T790M mutation diagnosed by repeated genetic testing in a patient with lung adenocarcinoma harboring epidermal growth factor receptor mutations: A case report. <i>Respiratory Medicine Case Reports</i> . 2018, 25, 261-263.	0.2	5
60	Nab-paclitaxel maintenance therapy following carboplatin + nab-paclitaxel combination therapy in chemotherapy naïve patients with advanced non-small cell lung cancer: multicenter, open-label, single-arm phase II trial. <i>Investigational New Drugs</i> , 2018, 36, 903-910.	1.2	5
61	Treatment rationale and design of the RAMNITA study. <i>Medicine (United States)</i> , 2018, 97, e11084.	0.4	5
62	Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer. <i>Investigational New Drugs</i> , 2019, 37, 291-296.	1.2	4
63	Randomized Phase II Study of Weekly Paclitaxel plus Carboplatin Versus Biweekly Paclitaxel plus Carboplatin for Patients with Previously Untreated Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1420-e1010.	1.9	4
64	Erlotinib as standard adjuvant therapy for resectable EGFR mutation-positive non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, S369-S372.	1.3	4
65	Phase II Study on Biweekly Combination Therapy of Gemcitabine plus Carboplatin for the Treatment of Elderly Patients with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, 208-e417.	1.9	4
66	Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged ≥75 years) with non-small cell lung cancer: A retrospective analysis. <i>Thoracic Cancer</i> , 2020, 11, 2867-2876.	0.8	4
67	Early discontinuation of induction therapy in chemoimmunotherapy as an effective alternative to the standard regimen in patients with non-small cell lung cancer: a retrospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2437-2446.	1.2	4
68	TTF-1 and c-MYC-defined Phenotypes of Large Cell Neuroendocrine Carcinoma and Delta-like Protein 3 Expression for Treatment Selection. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 313-320.	0.6	4
69	The Impact of Immune-related Adverse Events on the Effect of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer. <i>Japanese Journal of Lung Cancer</i> , 2019, 59, 128-136.	0.0	4
70	Editorial: Treatment for Non-Small Cell Lung Cancer in Distinct Patient Populations. <i>Frontiers in Oncology</i> , 2022, 12, 838570.	1.3	4
71	Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1033-e617.	1.9	3
72	Rationale and design of a phase II trial of osimertinib as first-line treatment for elderly patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer (SPIRAL-0)	0.0	0

#	ARTICLE	IF	CITATIONS
73	A Phase II Study of Sâ€1 and Paclitaxel Combination Therapy as a Firstâ€Line Treatment in Elderly Patients with Advanced Nonâ€Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 459.	1.9	3
74	Respiratory complications of Stevens-Johnson syndrome (SJS): 3 cases of SJS-induced obstructive bronchiolitis. <i>Allergy International</i> , 2020, 69, 465-467.	1.4	3
75	The Quality of Life of Patients with Suspected Lung Cancer before and after Bronchoscopy and the Effect of Mirtazapine on the Depressive Status. <i>Internal Medicine</i> , 2020, 59, 1605-1610.	0.3	3
76	Prognostic factors in older patients with wild-type epidermal growth factor receptor advanced non-small cell lung cancer: a multicenter retrospective study. <i>Translational Lung Cancer Research</i> , 2021, 10, 193-201.	1.3	2
77	Elevation of serum C-reactive protein predicts failure of the initial antimicrobial treatment for febrile neutropenia with lung cancer. <i>Journal of Infection and Chemotherapy</i> , 2013, 19, 202-207.	0.8	1
78	Pulmonary MALT Lymphoma Demonstrating a Crazy-paving Appearance on Imaging. <i>Internal Medicine</i> , 2015, 54, 2705-2706.	0.3	1
79	The impact of the tumor shrinkage by initial EGFR inhibitors according to the detection of EGFR-T790M mutation in patients with non-small cell lung cancer harboring EGFR mutations. <i>BMC Cancer</i> , 2018, 18, 1241.	1.1	1
80	Rationale and design of a phase II study to evaluate prophylactic treatment of dacomitinib-induced dermatologic adverse events in epidermal growth factor receptor-mutated advanced non-small cell lung cancer (SPIRAL-Daco study). <i>Translational Lung Cancer Research</i> , 2019, 8, 519-523.	1.3	1
81	Phase I/II Study of Docetaxel and S-1 in Previously-Treated Patients with Advanced Non-Small Cell Lung Cancer: LOGIK0408. <i>Journal of Clinical Medicine</i> , 2019, 8, 2196.	1.0	1
82	Serum immune modulators during the first cycle of antiâ€PDâ€1 antibody therapy in nonâ€small cell lung cancer: Perforin as a biomarker. <i>Thoracic Cancer</i> , 2020, 11, 3223-3233.	0.8	1
83	Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2985-2994.	1.2	1
84	An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer. <i>Medicine (United States)</i> , 2018, 97, e12660.	0.4	0
85	Osimertinib in first line setting: for Asian patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 550-552.	1.3	0
86	Can the assessment of lymphocyte exhaustion serve as a prognostic predictor after lung cancer surgery?. <i>Translational Lung Cancer Research</i> , 2020, 9, 184-187.	1.3	0
87	Randomized Phase II Study of Firstâ€Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Nonâ€Small Cell Lung Cancer: LOGIK0801. <i>Oncologist</i> , 2020, 25, e1146-e1157.	1.9	0
88	Overexpression of I.KAPPA.B.ALPHA. Suppresses Lung Cancer Growth Through Reduced VEGF Production. <i>Japanese Journal of Lung Cancer</i> , 2005, 45, 13-18.	0.0	0
89	A New Cancer Cell Detection Method Using an Infectivity-enhanced Adenoviral Vector. <i>Asian Pacific Journal of Cancer Prevention</i> , 2012, 13, 5551-5556.	0.5	0
90	Chronic Obstructive Pulmonary Diseases-Like Pathologic Changes by Chronic Infection of <i>Pseudomonas aeruginosa</i> in CCSP-Deficient Mice. <i>Open Forum Infectious Diseases</i> , 2015, 2, .	0.4	0

#	ARTICLE	IF	CITATIONS
91	Education Program for Male Patients with Chronic Obstructive Pulmonary Disease to Change Dietary Behavior. Kobe Journal of Medical Sciences, 2020, 66, E82-E89.	0.2	0